Pre­ci­Point has com­pleted a seven-digit growth financ­ing round in spring 2020. The round was led by bm|t and sup­ported by all other exist­ing investors, who showed their con­tin­ued com­mit­ment to the com­pany. The sig­nif­i­cant invest­ment will be used to fund the next stage in the company´s devel­op­ment. “We are very delighted to invest in PreciPoint´s strong team, its tech­nol­ogy and its vision to fight can­cer“, com­mented Ste­fan Jahn, Senior Invest­ment Man­ager at bm|t. Pre­ci­Point deliv­ers scal­able solu­tions for auto­mated dig­i­ti­za­tion and ana­lyt­ics for microscopy work­flows. Pre­ci­Point thus tack­les a key chal­lenge in can­cer diag­nos­tics. Its solu­tions and prod­ucts enable a wide range of qual­ity, effec­tive­ness, and effi­ciency gains for users. As dig­i­tal microscopy accel­er­ates work­flows Pre­ci­Point enables new busi­ness mod­els and modes of col­lab­o­ra­tion and improves qual­ity of output.

Today, almost 100% of micro­scopic analy­sis in life sci­ences is still per­formed man­u­ally. While dig­i­tal microscopy has been around for quite some time, adop­tion in the past has been slow. Can­cer tis­sue, sperm, yeast or plants, among oth­ers, are still analysed using ana­logue micro­scopes — which is not that dif­fer­ent com­pared to 30–40 years ago. That is expected to change. “We expect the 2020ies to be remem­bered as the decade when microscopy went truly dig­i­tal”, Nico­las Weiss and Dominik Ger­ber, the CEOs of Pre­ci­Point, con­fi­dently state. Dur­ing the next 5 to 10 years, the mar­ket for micro­scopic can­cer diag­nos­tics alone will grow to 3–5 bil­lion EUR p.a. Pre­ci­Point aims to shape this mar­ket and par­tic­i­pate in its rapid growth.

Pre­ci­Point offers inno­v­a­tive microscopy hard­ware and robot­ics to mul­ti­ply through­put and its cus­tomiz­able and scal­able soft­ware solu­tions allow for smooth inte­gra­tion into exist­ing work­flows. Pre­ci­Point dis­tin­guishes itself clearly from other mar­ket par­tic­i­pants by pro­vid­ing full solu­tions tai­lored to spe­cific use cases, rather than focus­ing on microscopy hard­ware alone. While its research solu­tions are already cur­rently sold to users all across the globe, the com­pany has ambi­tious plans to fuel future growth. In the pipeline are AI- and blockchain-appli­ca­tions and an exten­sive patent port­fo­lio to rein­force and pro­tect its tech­nol­ogy. The com­pany has also made sig­nif­i­cant progress to estab­lish part­ner­ships with well-known seg­ment spe­cial­ists and to attain inter­na­tional med­ical cer­ti­fi­ca­tions, both of which will sig­nif­i­cantly boost the company´s mar­ket access and reach. Pre­ci­Point now has over 40 employ­ees in two loca­tions in Thuringia and Bavaria. Its team is extremely diverse, bring­ing together, for exam­ple, soft­ware engi­neers and PhDs in physics and biol­ogy with busi­ness man­age­ment grad­u­ates and a highly skilled pro­duc­tion team. Employ­ing an almost equal share of women and men, the age range spans from 19 to 65 years of age. All employ­ees are extremely pas­sion­ate about Pre­ci­Point, its cul­ture and its ambi­tion. “The team has an excel­lent bal­ance between tech­nol­ogy and busi­ness lead­ers. The firm def­i­nitely has the poten­tial to be a dri­ving force in dig­i­tal microscopy and can­cer diag­nos­tics in the years ahead. We are very excited to be part of it”, stated Ste­fan Jahn, bm|t.

bm|t is the first address for invest­ments in Thürin­gen, Ger­many. bm|t invests in start-up teams and com­pa­nies in the Free State with a clear aim of gen­er­at­ing pos­i­tive invest­ment returns. This is how inno­va­tion and eco­nomic growth in Thürin­gen are financed. bm|t cur­rently man­ages eight funds with a total vol­ume of over 400 mil­lion euros and invests in inno­v­a­tive com­pa­nies in nearly all sec­tors and in all phases of com­pany devel­op­ment — from the start-up and growth phases to buy­outs and other suc­ces­sion sit­u­a­tions. For more infor­ma­tion visit www.bm‑t.com.

Pre­ci­Point is a dig­i­tal microscopy start-up, offer­ing microscopy hard­ware and robot­ics in con­nec­tion with exist­ing lab­o­ra­tory man­age­ment sys­tems and soft­ware pow­ered ana­lyt­ics to com­pre­hen­sively dig­i­tize microscopy work­flows. The com­pany aims to take a lead­ing posi­tion in can­cer diag­nos­tics. Its solu­tions and prod­ucts enable a wide range of qual­ity, effec­tive­ness, and effi­ciency gains for users. As dig­i­tal microscopy accel­er­ates work­flows, Pre­ci­Point enables new busi­ness mod­els and modes of col­lab­o­ra­tion while improv­ing qual­ity of out­put. Pre­ci­Point dif­fer­en­ti­ates itself by pro­vid­ing full solu­tions tai­lored to spe­cific use cases, an excep­tional and inno­v­a­tive prod­uct offer­ing, and a laser focus on client needs all with the high­est qual­ity devel­oped and made in Ger­many. For more infor­ma­tion visit www.precipoint.com.